7C6A
Crystal structure of AT2R-BRIL and SRP2070_Fab complex
Summary for 7C6A
Entry DOI | 10.2210/pdb7c6a/pdb |
Related | 7C61 |
Descriptor | IgG Light Chain, IgG heavy chain, Type-2 angiotensin II receptor,Soluble cytochrome b562,Type-2 angiotensin II receptor, ... (4 entities in total) |
Functional Keywords | gpcr, bril, crystallization, antibody, signaling protein |
Biological source | Mus musculus More |
Total number of polymer chains | 4 |
Total formula weight | 96977.76 |
Authors | Suzuki, M.,Miyagi, H.,Asada, H.,Yasunaga, M.,Suno, C.,Takahashi, Y.,Saito, J.,Iwata, S. (deposition date: 2020-05-21, release date: 2020-07-29, Last modification date: 2024-10-30) |
Primary citation | Miyagi, H.,Asada, H.,Suzuki, M.,Takahashi, Y.,Yasunaga, M.,Suno, C.,Iwata, S.,Saito, J.I. The discovery of a new antibody for BRIL-fused GPCR structure determination. Sci Rep, 10:11669-11669, 2020 Cited by PubMed Abstract: G-protein-coupled receptors (GPCRs)-the largest family of cell-surface membrane proteins-mediate the intracellular signal transduction of many external ligands. Thus, GPCRs have become important drug targets. X-ray crystal structures of GPCRs are very useful for structure-based drug design (SBDD). Herein, we produced a new antibody (SRP2070) targeting the thermostabilised apocytochrome b562 from Escherichia coli M7W/H102I/R106L (BRIL). We found that a fragment of this antibody (SRP2070Fab) facilitated the crystallisation of the BRIL-tagged, ligand bound GPCRs, 5HT and ATR. Furthermore, the electron densities of the ligands were resolved, suggesting that SPR2070Fab is versatile and adaptable for GPCR SBDD. We anticipate that this new tool will significantly accelerate structure determination of other GPCRs and the design of small molecular drugs targeting them. PubMed: 32669569DOI: 10.1038/s41598-020-68355-x PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.4 Å) |
Structure validation
Download full validation report
